These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 31505228)
1. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Kebriaei P; Hayes J; Daly A; Uberti J; Marks DI; Soiffer R; Waller EK; Burke E; Skerrett D; Shpall E; Martin PJ Biol Blood Marrow Transplant; 2020 May; 26(5):835-844. PubMed ID: 31505228 [TBL] [Abstract][Full Text] [Related]
2. Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children. Kurtzberg J; Prockop S; Chaudhury S; Horn B; Nemecek E; Prasad V; Satwani P; Teira P; Hayes J; Burke E; Biol Blood Marrow Transplant; 2020 May; 26(5):855-864. PubMed ID: 32044400 [TBL] [Abstract][Full Text] [Related]
3. A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease. Kurtzberg J; Abdel-Azim H; Carpenter P; Chaudhury S; Horn B; Mahadeo K; Nemecek E; Neudorf S; Prasad V; Prockop S; Quigg T; Satwani P; Cheng A; Burke E; Hayes J; Skerrett D; Biol Blood Marrow Transplant; 2020 May; 26(5):845-854. PubMed ID: 32018062 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556 [TBL] [Abstract][Full Text] [Related]
6. Remestemcel-L for the treatment of graft versus host disease. Locatelli F; Algeri M; Trevisan V; Bertaina A Expert Rev Clin Immunol; 2017 Jan; 13(1):43-56. PubMed ID: 27399600 [TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial. Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930 [TBL] [Abstract][Full Text] [Related]
8. Treatment of Steroid-Refractory Acute Graft- Murata M; Teshima T Front Immunol; 2021; 12():724380. PubMed ID: 34489977 [TBL] [Abstract][Full Text] [Related]
9. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. Zhao K; Lin R; Fan Z; Chen X; Wang Y; Huang F; Xu N; Zhang X; Zhang X; Xuan L; Wang S; Lin D; Deng L; Nie D; Weng J; Li Y; Zhang X; Li Y; Xiang AP; Liu Q J Hematol Oncol; 2022 Mar; 15(1):22. PubMed ID: 35255929 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSC PLEB001) for the treatment of grade II-IV steroid-refractory acute graft-versus-host disease: a study protocol for a multicenter, randomized, double-blind, placebo-controlled, phase II trial. Yang D; Hou X; Qian K; Li Y; Hu L; Li L; Han M; Yao C; Liu D Trials; 2023 May; 24(1):306. PubMed ID: 37138332 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092 [TBL] [Abstract][Full Text] [Related]
12. Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study. Kim N; Min GJ; Im KI; Nam YS; Song Y; Lee JS; Oh EJ; Chung NG; Jeon YW; Lee JW; Cho SG Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928436 [TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons. Tremblay G; Tomaras D; Strati E; Forsythe A J Health Econ Outcomes Res; 2021 Feb; 8(1):10-17. PubMed ID: 33768123 [No Abstract] [Full Text] [Related]
14. A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease. Soder RP; Dawn B; Weiss ML; Dunavin N; Weir S; Mitchell J; Li M; Shune L; Singh AK; Ganguly S; Morrison M; Abdelhakim H; Godwin AK; Abhyankar S; McGuirk J Stem Cell Rev Rep; 2020 Oct; 16(5):979-991. PubMed ID: 32740891 [TBL] [Abstract][Full Text] [Related]
15. Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up. Niu JW; Li Y; Xu C; Sheng H; Tian C; Ning H; Hu J; Chen J; Li B; Wang J; Lou X; Liu N; Su Y; Sun Y; Qiao Z; Wang L; Zhang Y; Lan S; Xie J; Ren J; Peng B; Wang S; Shi Y; Zhao L; Zhang Y; Chen H; Zhang B; Hu L Front Immunol; 2024; 15():1436653. PubMed ID: 39211037 [TBL] [Abstract][Full Text] [Related]
16. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325 [TBL] [Abstract][Full Text] [Related]
17. Extended Treatment With Mesenchymal Stromal Cells-Frankfurt am Main in a Pediatric Patient With Steroid-refractory Acute Gastrointestinal Graft-Versus-Host Disease: Case Report and Review of the Literature. Gruhn B; Brodt G; Ernst J J Pediatr Hematol Oncol; 2021 Apr; 43(3):e419-e425. PubMed ID: 32118816 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease. Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053 [TBL] [Abstract][Full Text] [Related]
19. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease. Ding Y; Liu C; Cai Y; Hou C; Chen G; Xu Y; Hu S; Wu D Clin Exp Med; 2023 Oct; 23(6):2561-2570. PubMed ID: 36598673 [TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study. Herrmann R; Sturm M; Shaw K; Purtill D; Cooney J; Wright M; Phillips M; Cannell P Int J Hematol; 2012 Feb; 95(2):182-8. PubMed ID: 22183779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]